From 1994 to 2000, Dr. Cauwenbergh served as Global Vice President of Research & Development at Johnson & Johnson Consumer Companies Worldwide. He served as Vice President, Research and Development for Johnson & Johnson's Skin Research Center, and was responsible for the worldwide research and development of all skin care products for the Johnson & Johnson consumer companies. Dr. Cauwenbergh served as Vice President, Product Development and a Member of the Management Board of U.S. J&J Consumer Company since 1994. He served as the Director of Corporate Skin Care Council of J&J, co-ordinating all skin care activities in the different operating groups of Corporation. In his career, he served positions in sales, and national and international marketing, and he was responsible for the successful global introduction of Nizoral (ketoconazole). His R&D activities had also involved him in the fields of psoriasis, acne, wound healing, atopic dermatitis, protozoal infections, and HIV. He serves as the Executive Chairman of ECI Biotech. He serves as the Chairman of Expressive Constructs, Inc. He served as the Chairman of BioNJ Inc. He has been a Director of RXi Pharmaceuticals Corporation since May 2012. He has been a Director of Euroscreen S.A since July 2008, Cutanea Life Sciences Inc. since July 9, 2010, Phosphagenics Limited since March 3, 2014 and Moberg Pharma AB (publ) (alternate name: Moberg Derma AB) since April 23, 2012. He serves as a Director of RHEI. He served as an Independent Director of Ablynx NV until April 25, 2013. He served as a Member of the Board of Intercept Inc. (US), from 2003 to 2005. He served as a Director of Upstream Biosciences, Inc. from March 25, 2008 to December 14, 2009. He served as a Director of DARA BioSciences, Inc. from June 14, 2008 to April 4, 2009.
Dr. Geert Cauwenbergh, Ph.D., Med.Sc. has been the Chief Executive Officer and President of RXi Pharmaceuticals Corporation since April 27, 2012, and serves as its Acting Chief Financial Officer. Dr. Cauwenbergh has been the Head of International Advisory Board at Skinvisible Inc. since November 2008. He has been Business Advisor of Edge Therapeutics, Inc., since June 2010. He has been the Official Trade Advisor to the Belgian Government for Health Care in the USA since 2004. He has more than 20 years experience in international research, clinical drug development and new product commercialization for both specialty pharmaceuticals and anti-infectives at both pharmaceutical and biotechnology companies, including Johnson & Johnson (J&J) and the Janssen Research Foundation in Belgium. Dr. Cauwenbergh served as the Chief Executive Officer of RHEI Pharmaceuticals Inc., from August 1, 2008 to June 2011 and also served as its Chairman. He served as Managing Director of the Center for Medical Innovation, a government subsidized center for translational medicine for the Belgian Region of Flanders. Prior to joining RHEI Pharmaceuticals in February 2008, he was a founder and Chief Executive Officer of Phases123, LLC. He founded Barrier Therapeutics Inc. in September 2001 and served as its Executive Chairman from September 2001 to June 2006, Chief Executive Officer from September 2001 to March 31, 2008 and also served as its President. He founded Aramis LLC in May 2009. Prior to founding Barrier, Dr. Cauwenbergh held a number of ascending senior management positions at Johnson & Johnson, where he was employed for 23 years. He served at Johnson & Johnson (in both the U.S. and Europe) Consumer and Personal Care Products Companies from 2000 to 2002, where Dr. Cauwenbergh served as Vice President of Technology, where he created technology platforms based on intellectual property and know-how owned by it and developed a business proposition around these platforms.
A meaningful event? Anyone?.................thanks
autumn, many thanks for your hard work. Let,s see what the next few month may bring INIS's way..........
Most here do not trade in the stock of $40m market cap experimental biotech stocks hanna. Personally I think its crazy. There is no action here at present.
I like the science, the expanded IP, and especially the management. I"m in for long term. I have a very good feeling that the good Doctor has something in store..................good luck All
Much appreciated crybaby, but not under the skin whatsoever. He does not possess such an ability. I just expose the criminal to others who may not be hep to his agenda.
Good luck All
His direct quotes from previous responses to me ;
1. quote: "altruism and to share ideas with fellow investors. How's that? Satiate your need to "know?"
2. quote: "What if I said I like to translate thoughts into words and this is my canvas?"
3. quote: " I am only here to help you."
Personally I like #3.
Good luck All
You do enjoy talking down to people don't you. I suppose that's why nobody likes you, that is except for one perhaps.
Looks like you just ask for me to expose you for the miscreant that you are. I shall post some of your more memorable comments when I get the time.
See folks he goes crazy when I expose his motives. Criminals do not like attention....................Good luck all
Autumn, many thanks for the info. Slowly but surely RXI is gaining traction. It is my opinion that Cauwenbergh is taking all the right steps. He is an old pro, been there many times, has extensive associations from his 20+ years heading J&J's entire worldwide skincare division, and is surrounded by the same experience in his staff, ( just to mention Dr. Pavco), and impressive BOD's.
Not quite sure I'd be here without him.............good luck All
hanna, 100K shares traded with a 2 cent move in an R&D 40m M/C company and you thing something is going on. How you blow with the wind. Either you are afraid of your own shadow, you can not handle this type investment, you are here to soft bash, you work with hedgrslk, or whatever,
Bullish or bearish three times per week? Ger a hold of yourself will you...........